Android app on Google Play

Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report

November 19, 2012 9:03 AM EST Send to a Friend
Get Alerts LGND Hot Sheet
Trade LGND Now!
Join SI Premium – FREE
Ligand Pharmaceuticals (NASDAQ: LGND), GSK's (NYSE: GSK) promacta approved for treatment of low blood platelet counts in HepC patients, Adam Feuerstein reports.




You May Also Be Interested In


Related Categories

FDA, Trader Talk

Add Your Comment